Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN16300009) titled 'Description of the quality of life of patients with neovascular age-related macular degeneration initiating or switching to faricimab in the real-world setting' on Sept. 7.
Study Type: Observational
Study Design:
Longitudinal study
Primary Sponsor: Roche (France)
Condition:
Patient suffering from neovascular age-related macular degeneration.
Eye Diseases
Intervention:
The FARILIFE study is a French, national, multicenter, prospective, primary data collection, non-interventional study of two cohorts of nAMD patients, treatment-naive ("Naive" cohort) or previously treated with an anti-VEGF ("Switch" cohort),...